A detailed history of Bank Of America Corp transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 434,299 shares of HRTX stock, worth $825,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares
434,299
Previous 235,042 84.78%
Holding current value
$825,168
Previous $651,000 133.49%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.32 - $3.86 $462,276 - $769,132
199,257 Added 84.78%
434,299 $1.52 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.06 $83,044 - $148,605
48,564 Added 26.04%
235,042 $651,000
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $67,980 - $229,117
125,889 Added 207.78%
186,478 $317,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.88 $50,413 - $130,803
-45,418 Reduced 42.84%
60,589 $70,000
Q1 2023

May 12, 2023

SELL
$1.51 - $3.25 $14,479 - $31,164
-9,589 Reduced 8.3%
106,007 $160,000
Q4 2022

Feb 10, 2023

SELL
$2.25 - $4.67 $1.02 Million - $2.11 Million
-451,260 Reduced 79.61%
115,596 $288,000
Q3 2022

Nov 14, 2022

SELL
$2.66 - $5.37 $425,815 - $859,634
-160,081 Reduced 22.02%
566,856 $2.39 Million
Q2 2022

Aug 12, 2022

SELL
$2.3 - $6.29 $2.02 Million - $5.53 Million
-879,907 Reduced 54.76%
726,937 $2.03 Million
Q1 2022

May 16, 2022

BUY
$4.63 - $9.94 $5.84 Million - $12.5 Million
1,261,600 Added 365.42%
1,606,844 $9.19 Million
Q4 2021

Feb 08, 2022

BUY
$8.35 - $12.6 $1.99 Million - $3.01 Million
238,708 Added 224.06%
345,244 $3.15 Million
Q3 2021

Nov 15, 2021

SELL
$10.13 - $15.0 $167,479 - $247,995
-16,533 Reduced 13.43%
106,536 $1.14 Million
Q2 2021

Sep 13, 2021

BUY
$13.27 - $18.48 $1.63 Million - $2.27 Million
123,069 New
123,069 $1.91 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $226M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.